Article Text

other Versions

PDF
Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension
  1. Anastasios G P Konstas1,
  2. Luciano Quaranta2,
  3. Andreas Katsanos3,
  4. Ivano Riva2,
  5. James C Tsai4,
  6. Theodoros Giannopoulos1,
  7. Irini C Voudouragkaki1,
  8. Eleni Paschalinou1,
  9. Irene Floriani5,
  10. Anna-Bettina Haidich6
  1. 1Glaucoma Unit, 1st University Department of Ophthalmology, Aristotle University, AHEPA Hospital, Thessaloniki, Greece
  2. 2Centre for the Study of Glaucoma, University of Brescia, Brescia, Italy
  3. 3Ophthalmology Department, University of Ioannina, Ioannina, Greece
  4. 4Department of Ophthalmology and Visual Science, Yale Eye Center, Yale University School of Medicine, New Haven, Connecticut, USA
  5. 5IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
  6. 6Department of Hygiene, Aristotle University, Thessaloniki, Greece
  1. Correspondence to Professor A G P Konstas, Glaucoma Unit, 1st University Department of Ophthalmology, Aristotle University, AHEPA Hospital, 1 Kyriakidi Street, Thessaloniki 546 36, Greece; konstas{at}med.auth.gr

Abstract

Aim To compare 24 h intraocular pressure (IOP) control obtained with preservative free (PF) tafluprost 0.0015% versus branded preservative containing latanoprost 0.005% administered as first choice monotherapy in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT).

Methods This prospective, observer-masked, crossover study included consecutive newly diagnosed patients with POAG or OHT, and baseline IOP between 24 and 33 mm Hg. Qualifying patients underwent baseline untreated 24 h IOP monitoring in habitual positions, with Goldmann tonometry at times 10:00, 14:00, 18:00 and 22:00, and Perkins supine tonometry at times 02:00 and 06:00. They were then randomised to either latanoprost or tafluprost, administered in the evening, for 3 months and then switched to the opposite therapy for another 3 months. 24 h monitoring was repeated at the end of each treatment period.

Results 38 patients completed the study. Mean untreated 24 h IOP (24.9 mm Hg) was significantly reduced with both prostaglandins (p<0.001). Tafluprost demonstrated similar mean 24 h efficacy compared with latanoprost (17.8 vs 17.7 mm Hg; p=0.417). Latanoprost demonstrated significantly better 24 h trough IOP (15.9 vs 16.3 mm Hg; p=0.041) whereas tafluprost provided significantly lower 24 h IOP fluctuation (3.2 vs 3.8 mm Hg; p=0.008). No significant difference existed between the two prostaglandins for any adverse event.

Conclusions PF tafluprost achieved similar 24 h IOP reduction to branded latanoprost. The current study highlights the importance of complete assessment of efficacy over 24 h.

Clinical trials registration NCT01162603.

  • Clinical Trial
  • Drugs
  • Glaucoma
  • Intraocular pressure
  • Treatment Medical

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles